Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 6Other hematologic neoplasm 4Tumor-Agnostic 3Gynecologic 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 265Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 145Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Antineoplastic Agents × Breast × Clear all
NCT03591276 2020-10-23

KEYDOX

Shaare Zedek Medical Center

Phase 1/2 Recruiting
15 enrolled
Breast

Breast Neoplasms

NCT03799679 2019-01-10

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Fudan University

Phase 4 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡